WEIGHT MANAGEMENT PROGRAMME

The Effect Doctors Weight Management Programme combines a comprehensive and holistic assessment by our medical team, bespoke weight loss advice and planning and safe access to prescription only weight loss medications.

The cost of initial consultation is £400

The repeat prescription cost is £250 per month

 

  • What is Saxenda (Liraglutide)
    • Saxenda® is an injectable prescription medicine that, when used with a reduced-calorie diet and increased physical activity, may help adults with obesity or overweight (excess weight) who also have weight-related medical problems

      Initially approved for the treatment of diabetes, Saxenda contains the medication Liraglutide, a synthetic version of a glucagon-like peptide-1 hormone that works by slowing stomach emptying, increasing satiety, and reducing hunger.

      It is delivered by once daily injections.

      Weight loss from this medication was reported during trials:

      • 63% lost at least 5% of body weight
      • 33% lost at least 10% body weight
      • 15% lost at least 15% of body weight

      And 80% of participants kept the weight off at one year.

      Ask our medical team about Saxenda today

  • What is Ozempic (Semaglutide)
    • This once weekly injectable medication contains, Semaglutide, a synthetic version of a glucagon-like peptide-1 hormone that affects appetite and hunger. In trials, 75% of patients lost over 10% of their body weight.

      Like all GLP-1 analogues, it works by slowing stomach emptying, increasing satiety, and reducing hunger.

      What’s the difference between Saxenda and Ozempic:

      • Ozempic is a once weekly injection, rather than once a day.
      • Ozempic has been shown to be mire effective in longer term weight management.
      • At the moment, Ozempic is prescribed off-label for weight loss, as it is not licenced for weight-loss (only management of diabetes)

      Ask our medical team about Ozempic today

  • What is Wegovy (Semaglutide)
    • Wegovy is the exciting new injectable weight loss drug, specifically targeting medical weight loss; it is a synthetic version of a glucagon-like peptide-1 hormone that affects appetite and hunger.

      Wegovy is an FDA approved preparation of Semaglutide, licenced specifically for weight loss, which at present is not licenced in the UK. Approval is expected at some point in late 2022 or early 2023.

      The starting dose for Wegovy, will likely be higher than Ozempic.

      Like all GLP-1 analogues, it works by slowing stomach emptying, increasing satiety, and reducing hunger.

      During clinical trials to evaluate the safety of Wegovy when used for treating obesity, participants without diabetes who were prescribed Wegovy lost on average, 12.4% of their initial body weight when compared to a placebo.

      Studies show you will lose about 5% of your body weight within 3 months

      Coming Soon